

INVERNESS MEDICAL INNOVATIONS INC

Form 8-K

November 19, 2002

[QuickLinks](#) -- Click here to rapidly navigate through this document

---

---

## SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

### FORM 8-K

#### CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) November 14, 2002

### Inverness Medical Innovations, Inc.

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**001-16789**  
(Commission file number)

**04-3565120**  
(I.R.S. Employer  
Identification No.)

**51 Sawyer Road, Suite 200, Waltham, Massachusetts 02453**  
(Address of principal executive offices)  
**Registrant's telephone number, including area code: (781) 647-3900**

**Not Applicable**  
(Former name or former address, if changed since last report)

---

---

---

#### ITEM 5. OTHER EVENTS.

On November 14, 2002, Inverness Medical Innovations, Inc. (the "Company") and certain of its subsidiaries entered into a credit agreement (the "Credit Agreement") with a group of banks for credit facilities in the aggregate amount of \$55,000,000. The Credit Agreement consists of a US term loan of \$20,000,000, a European term loan of \$10,000,000, and a \$25,000,000 European revolving line of credit. Aggregate borrowings as of November 15, 2002, amounted to \$30,000,000 under the term loans and \$23,000,000 under the revolving line of credit. The Company used approximately \$44,110,000 of the proceeds from the loans under the Credit Agreement to prepay, as of November 15, 2002, the entire outstanding principal balance and all accrued and unpaid interest on the term loans and line of credit under its credit agreements with the Royal Bank of Scotland Plc and RBS Mezzanine Limited, and to thereby terminate these credit agreements and all security arrangements related thereto.

Under the Credit Agreement, principal repayments under the US term loan are to be made in 11 equal quarterly installments of \$1,250,000 starting on April 30, 2003 through October 31, 2005 with a final repayment of \$6,250,000 in November 2005. Principal repayments under the European term loan are to be made in 14 equal quarterly installments of \$25,000 starting on January 31, 2003 through April 30, 2006 with a final repayment of \$9,650,000 in May 2006. Any borrowings under the revolving line of credit will mature on November 13, 2005. Borrowings under the term loans and the revolving line of credit bear interest at either (i) the London Interbank Offered Rate ("LIBOR"), as defined, plus



**Exhibit  
Number**

**Description**

---

99.1	Credit Agreement dated as of November 14, 2002 among Wampole Laboratories, Inc. and Inverness Medical (UK) Holdings Limited, as Borrowers, the other credit parties signatory thereto, as Credit Parties, the lenders signatory thereto from time to time, as Lenders, General Electric Capital Corporation, as Agent and Lender and KeyBank National Association, as Documentation Agent and Lender, with GECC Capital Markets Group, Inc., as Lead Arranger.
------	--

5

---

QuickLinks

[SIGNATURE](#)

[EXHIBIT INDEX](#)